Increased sensitivity to the hepatocarcinogen diethylnitrosamine in transgenic mice carrying the hepatitis B virus X gene

Molecular Carcinogenesis

Volumn 15, Issue 4, 1996, Pages 261-269

  Slagle, Betty L ^a   Lee, Teh Hsiu ^a   Medina, Daniel ^a   Finegold, Milton J ^a   Butel, Janet S ^a  

^a BAYLOR COLLEGE OF MEDICINE   (United States)

Author keywords

Carcinogen; HBV X protein; Hepatitis B virus; Liver disease; Transgenic mice

Indexed keywords

DIETHYLNITROSAMINE; HBV X PROTEIN; PROTEIN P53; UNCLASSIFIED DRUG;

ANIMAL EXPERIMENT; ANIMAL MODEL; ANIMAL TISSUE; ARTICLE; CONTROLLED STUDY; HEPATITIS B VIRUS; LIVER CARCINOGENESIS; MALE; MOUSE; NONHUMAN; PRIORITY JOURNAL; TRANSGENIC MOUSE; VIRUS GENE;

AGE FACTORS; ALKYLATING AGENTS; ANIMALS; CARCINOGENS; DIETHYLNITROSAMINE; DNA, VIRAL; DOSE-RESPONSE RELATIONSHIP, DRUG; FEMALE; GENE EXPRESSION REGULATION, VIRAL; GENES, VIRAL; HEPATITIS B VIRUS; LIVER NEOPLASMS; LIVER NEOPLASMS, EXPERIMENTAL; MALE; MICE; MICE, TRANSGENIC; TRANS-ACTIVATORS; VIRAL STRUCTURAL PROTEINS;

EID: 0029870749     PISSN: 08991987     EISSN: None     Source Type: Journal    
DOI: 10.1002/(SICI)1098-2744(199604)15:4<261::AID-MC3>3.0.CO;2-J     Document Type: Article

References (49)

1. Beasley RP, Hwang LY, Lin CC, Chien CS. Hepatocellular carcinoma and hepatitis B virus. A prospective study of 22 707 men in Taiwan Lancet 2:1129-1133, 1981.
2. Yeh F-S, Yu MC, Mo C-C, Luo S, Tong MJ, Henderson BE. Hepatitis B virus, aflatoxins, and hepatocellular carcinoma in southern Guangxi, China Cancer Res 49:2506-2509, 1989
3. Siegle BL, Lee TH, Butel JS. Hepatitis B virus and hepatocellular carcinoma. Review Prog Med Virol 39:167-203, 1992.
4. Buendia MA. Hepatitis B viruses and hepatocellular carcinoma. Review. Adv Cancer Res 59:167-226, 1992.
5. Chisan FV, Ferrari C. Hepatitis B virus immunopathogenesis. Annu Rev Immunol 13:29-60, 1995
6. Miller RH, Kaneko S, Chung CT, Girones R, Purcell RH Compact organization of the hepatitis B virus genome Hepatology 9:322-327, 1989
7. Rossner MT. Hepatitis B virus X-gene product: A promiscuous transcriptional activator. J Med Virol 36 101-117, 1992.
8. Takada S, Kido H, Fukutomi A, Mon T, Koike K. Interaction of hepatitis 8 virus X protein with a serine protease, tryptase TL2, as an inhibitor. Oncogene 9 341-348, 1994.
9. Kekulé AS, Lauer U, Weiss L, Luber B, Hofschneider PH. Hepatitis B virus transactivator HBx uses a tumour promoter signaling pathway. Nature 361:742-745, 1993.
10. De-Medina T, Haviv I, Noiman S, Shaul Y The X protein of hepatitis B virus has a ribo-deoxy ATPase activity. Virology 202.401-407, 1994.
11. Maguire HF, Hoeffler JP, Siddiqui A HBV X protein alters the DNA binding specificity of CREB and ATF-2 by protein-protein interactions. Science 252:842-844, 1991.
12. Cheong J-H, Yi M-K, Lin Y, Murakami S Human RPB5, a subunit shared by eukaryotic nuclear RNA polymerases, binds human hepatitis B virus X protein and may play a role in X transactivation. EMBO J 14:143-150, 1995.
13. Lee T-H, Elledge SJ, Butel JS. Hepatitis B virus X protein interacts with a probable cellular DNA repair protein J Virol 69:1107-1114, 1995.
14. Feitelson M. Hepatitis B virus infection and primary hepatocellular carcinoma, Review. Clin Microbiol Rev 5.275-301, 1992
15. Kay A, Mandart E, Trepo C. Galibert F. The HBV Hbx gene expressed in E coli is recognized by sera from hepatitis patients. EMBO J 4:1287-1292, 1985.
16. Moriarty AM, Alexander H, Lerner RA. Antibodies to peptides detect new hepatitis B antigen Serological correlation with hepatocellular carcinoma. Science 227.429-433, 1985
17. Pfaff E, Salfeld J, Gmelin K, Schaller H, Theilmann L. Synthesis of the X-protein of hepatitis B virus in vitro and detection of anti-X antibodies in human sera. Virology 158:456-460, 1987.
18. Kim C-M, Koike K, Saito I, Miyamura T, Jay G. HBx gene of hepatitis B virus induces liver cancer in transgenic mice. Nature 351.317-320, 1991.
19. Lee T-H, Finegold MF, Shen R-F, DeMayo JL, Woo SLC, Butel JS. Hepatitis B virus transactivator X protein is not tumorigenic in transgenic mice J Virol 64:5939-5947, 1990.
20. Dragani TA, Manenti G, Farza H, Della Porta G, Tiollais P, Pourcel C Transgenic mice containing hepatitis B virus sequences are more susceptible to carcinogen-induced hepatocarcinogenesis. Carcinogenesis 11-953-956, 1989
21. Scorsone KA, Zhou YZ, Butel JS, Slagle BL. p53 mutations cluster at codon 249 in hepatitis B virus-positive hepatocellular carcinomas from China. Cancer Res 52:1635-1638, 1992.
22. Bressac B, Kew M, Wands J, Ozturk M Selective G to T mutations of p53 gene in hepatocellular carcinoma from southern Africa. Nature 350.429-431, 1991
23. Hsu IC, Metcalf RA, Sun T, Welsh JA, Wang NJ, Harris CC Mutational hotspot in the p53 gene in human hepatocellular carcinomas. Nature 350.427-428, 1991
24. Moore MR, Drinkwater NR, Miller EC, Miller JA, Pitot HC. Quantitative analysis of the time-dependent development of glucose6-phosphatase-deficient foci in the livers of mice treated neonataily with diethylintrosamine. Cancer Res 41:1585-1593, 1981.
25. Jerry DJ, Butel JS, Donehower LA, et al. Infrequent p53 mutations in 7,12-dimethylbenz[a]anthracene-induced mammary tumors in BALB/c and p53 hemizygous mice. Mol Carcinog 9.175-183, 1994.
26. Sepulveda AR, Finegold MJ, Smith B, et al. Development of a transgenic mouse system for the analysis of stages in liver carcinogenesis using tissue-specific expression of SV40 large T-antigen controlled by regulatory elements of the human alpha-1-antitrypsin gene Cancer Res 49:6108-6117, 1989.
27. Slagle BL, Lanford RE, Medina D, Butel JS. Expression of mammary tumor virus proteins in preneoplastic outgrowth lines and mammary tumors of BALB/cV mice. Cancer Res 44:2155-2162, 1984.
28. Anthony PP, Vogal CH, Barker LF. Liver cell dysplasia. A premalignant condition. J Clin Path 26:217-223, 1973.
29. Smith ML, Yeleswarapu L, Locker J, Lombardi B. Expression of p53 mutant protein(s) in diethylnitrosamine-induced foci of enzyme-altered hepatocytes in male Fischer-344 rats. Carcinogenesis 12.1137-1141, 1991.
30. Jerry DJ, Ozbun MA, Kittrell FS, Lane DP, Medina D, Butel JS. Mutations in p53 are frequent in the preneoplastic stage of mouse mammary tumor development. Cancer Res 53:3374-3381, 1993.
31. Sell S, Hunt JM, Dunsford HA, Chisari FV Synergy between hepatitis B virus expression and chemical hepatocarcinogens in transgenic mice. Cancer Res 51:1278-1285, 1991.
32. Chisari FV, Klopchin K, Moriyama T, et al Molecular pathogenesis of hepatocellular carcinoma in hepatitis B virus transgenic mice Cell 59.1145-1156, 1989.
33. Hagen TM, Huang S, Curnutte J, et al. Extensive oxidative DNA damage in hepatocytes of transgenic mice with chronic active hepatitis destined to develop hepatocellular carcinoma. Proc Natl Acad Sci USA 91:12808-12812, 1994.
34. 6-benzylguanine provides a means to evaluate the role of this protein in protection against carcinogenic and therapeutic alkylating agents. Proc Natl Acad Sci USA 87:5368-5372, 1990.
35. 6-alkylguanine-DNA alkyltransferase. Science 259:219-222, 1993.
36. Kirby GM, Chemin I, Montesano R, Chisari FV, Lang MA, Wild CP Induction of specific cytochrome P450S involved in aflatoxin B1 metabolism in hepatitis B virus transgenic mice. Mol Carcinog 11.74-80, 1994
37. Hwang BJ, Chu G. Purification and characterization of a human protein that binds to damaged DNA. Biochemistry 32 1657-1666, 1993.
38. Keeney S, Eker APM, Brody T, et al. Correction of the DNA repair defect in xeroderma pigmentosum group E by injection of a DNA damage-binding protein. Proc Natl Acad Sci USA 91:4053-4056, 1994.
39. Takao M, Abramic M, Moss M Jr, et al. A 127 kDa component of a UV-damaged DNA-binding complex, which is defective in some xeroderma pigmentosum group E patients, is homologous to a slime mold protein. Nucleic Acids Res 21 4111-4118, 1993
40. Abramic M, Levine AS, Protic M Purification of an ultravioletinducible, damage-specific DNA-binding orotein from primate cells. J Biol Chem 266:22493-22500, 1991.
41. Payne A, Chu G Xeroderma pigmentosum group E binding factor recognizes a broad spectrum of DNA damage. Mutat Res 310 89-102, 1994.
42. Tokusashi Y, Fukuda I, Ogawa K Absence of p53 mutations and various frequencies of Ki-ras exon 1 mutations in rat hepatic tumors induced by different carcinogens. Mol Carcinog 10.45-51, 1994
43. Rumsby PC, Davies MJ, Evans JG, Screening for p53 mutations in C3H/He mouse liver tumors derived spontaneously or induced with diethylnitrosamine or phenobarbitone. Mol Carcinog 9:71-75, 1994
44. Chen B, Liu L, Castonguay A, Maronpot RR, Anderson MW, You M. Dose-dependent ras mutation spectra in N-nitrosodiethylamine induced mouse liver tumors and 4-(methylnitrosamino)-1-(3-pyridyl)-1-butanone induced mouse lung tumors Carcinogenesis 14.1603-1608, 1993
45. Truant R, Antunovic J, Greenblatt J, Prives C, Cromlish JA Direct interaction of the hepatitis B virus HBx protein with p53 leads to inhibition by HBx of p53 response element-directed transactivation. J Virol 69:1851-1859, 1995.
46. Feitelson MA, Zhu M, Duan LX, London WT. Hepatitis B × antigen and p53 are associated in vitro and in liver tissues from patients with primary hepatocellular carcinoma. Oncogene 8.1109-1117, 1993
47. Wang XW, Forrester K, Yeh H, Feitelson MA, Gu JR, Harris CC. Hepatitis B virus X protein inhibits p53 sequence-specific DNA binding, transcriptional activity, and association with transcription factor ERCC3 Proc Natl Acad Sci USA 91:2230-2234, 1994.
48. Ueda H, Ullrich SJ, Gangemi JD, et al. Functional inactivation but not structural mutation of p53 causes liver cancer Nat Genet 9-41 -47, 1995.
49. Greenblatt MS, Bennett WP, Hollstein M, Harris CC Mutations in the p53 tumor suppressor gene. Clues to cancer etiology and molecular pathogenesis. Cancer Res 54:4855-4878, 1994.